Apotex Inc v Sanofi‑Synthelabo Canada Inc

legal citation of this text
full work available at
Wikipedia creation date
Wikipedia incoming links count
Wikipedia opening text
Apotex Inc v Sanofi-Synthelabo Canada Inc, [2008] 3 S.C.R. 265, is a leading Supreme Court of Canada decision on the novelty and non-obviousness requirements for a patent in Canada. The Court rejected a challenge by the generic drug manufacturer Apotex to declare Synthelabo Canada's patent for Plavix, an anti-coagulant drug, invalid. At issue was whether selection patents are invalid in principle, and if they are not, whether the subject selection patent was invalid on the grounds of anticipation, obviousness or double patenting.
Wikipedia redirect
Apotex Inc. v. Sanofi‑Synthelabo Canada Inc.
Apotex Inc. v. Sanofi-Synthelabo Canada Inc.
Wikipedia URL